A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas

Status unconfirmed

Conditions studied: HIV Infection

In brief

Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Human Services. It has become a widely used antiretroviral therapy option for HIV infected patients. It provides good tolerability and a favorable lipid profile for patients when compared to some other antiretroviral treatment options. Little data is reported about efficacy in a minority patient population. Moreover, data in an indigent minority population in the United States has not been aggregated before. Therefore this study will investigate the efficacy of raltegravir in minority women residing in Houston, TX who are HIV infected.

Key facts

Study ID

NCT02302950

Run by

The University of Texas Health Science Center, Houston

People needed

254

Starts

2014-09-01

Expected to finish

2017-12-01

Last updated by the study team

2017-05-22

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• HIV-infected women who picked up raltegravir in the year 2013 at Thomas Street Health Center.
• Minority women -Black/African American, Hispanic/Latino

You may not qualify if…

• n/a

Where it is running

• Thomas Street Clinic — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.